Science News
Biointron Launches RushMab as Antibody Production Market Targets $39.8B by 2033
Grand View Research puts the global antibody production market at USD 15.44 billion for 2024, with projections of USD 39.80 billion by 2033, an 11.2 percent compound annual growth rate tied directly to the expansion of biologic drug pipelines and the rising volume of pre-clinical validation work being outsourced to specialist CROs. Biointron Biological Inc., a contract research organization based in Cambridge, Massachusetts, has launched Small-Scale Antibody Expression Packages under the RushMab™ brand, compressing antibody delivery timelines to as few as 10 days for purified, quality-controlled material. Pharma and biotech companies are outsourcing more pre-clinical work than ever before. The antibody contract manufacturing segment alone represented USD 34.72 billion in addressable opportunity as of 2026, per a market report published in April of that year via GlobeNewswire. Speed is now the primary variable. When expression turnaround runs long, candidate screening cycles slip with it, sometimes by weeks, and for research-stage companies working under tight capital constraints, those delays carry real cost. The shift has made fast, small-batch CRO capability a procurement priority rather than a convenience. For more information, visit https://www.biointron.com/antibody-production/rushmab-small-scale-expression-packages.html Recombinant antibody expression converts a sequence file into a functional protein a research team can actually use. Biointron's RushMab™ line covers that process at four delivery speeds. Teams that only need plasmid material can get 100 micrograms of transfection-grade expression plasmids from the RushMab™-Gene package in four days. RushMab™ Super adds purification and delivers antibody with titer detection in eight. Both Mini and Standard packages hit the 10-day mark with full purification: the Mini at a minimum of 100 micrograms, the Standard at over 1 milligram, with endotoxin testing below 1 EU/mg and SDS-PAGE plus SEC-HPLC verification on both. IgG, Fab, VHH, and ScFv formats are all supported, covering the structural range most common in early biologic research. Service details are on Biointron's Small-Scale Antibody Expression Packages page. Speed-to-delivery has become the main competitive axis in small-scale antibody expression. GenScript Biotech Corporation, listed on the Hong Kong Stock Exchange, runs a TurboCHO™ transient expression platform that publishes five-business-day turnaround for select configurations. Sino Biological cites a 10-day gene-to-antibody standard across its high-throughput recombinant service. Biointron competes at that same benchmark with the added breadth of IgG, Fab, VHH, and ScFv support in one service menu. ISO 9001:2015 certification and membership in MassBio – the Massachusetts life sciences industry association – round out the compliance profile that pharmaceutical procurement teams typically require. "As biologic pipelines grow and AI-driven candidate generation accelerates, the wet-lab expression step has become the rate-limiting factor in early research programs," said Mia Deng of Biointron Biological Inc. She noted that RushMab™ was built to keep pace with how fast modern discovery workflows now move. "A 10-day turnaround for a fully purified, endotoxin-tested antibody removes a friction point that used to cost teams weeks between candidate iterations." Biointron was founded in 2012. Since then it has delivered recombinant antibody services to more than 2,500 biotech and pharmaceutical organizations spanning more than 20 countries. In 2025, Scientist.com recognized the company with its Supplier Performance Recognition Award for drug discovery research services. Cambridge, Massachusetts, puts Biointron inside one of North America's most concentrated corridors for biologic research, academic medical centers, pharmaceutical research units, and venture-backed startups, all operating within close proximity and generating consistent demand for fast, reliable CRO output. The full range of Antibody Expression Packages is available on the company's website. About Biointron Biological Inc. Biointron Biological Inc . is a Cambridge, Massachusetts-based contract research organization specializing in antibody discovery, antibody production, stable cell line development, and protein expression services for biotech and pharmaceutical clients worldwide. Founded in 2012 and ISO 9001:2015 certified, Biointron has served more than 2,500 organizations across more than 20 countries.
Biointron Launches RushMab Packages to Deliver Purified Antibodies in 10 Days
Energy Crunch Spurs Ever Wonder Adventure To Advance Waste-To-Power Action Today
Creative Biolabs Launches Integrated Analytical Platform to Optimize Biomass and Biogas Fermentation
- May 27, 2026Science
Creative Biolabs Launches Integrated iPSC Reprogramming and Alzheimer's Disease Cell Model Platform
As the complexity of the human brain continues to challenge traditional research models, scientists are increasingly turning to human iPSC-derived neuronal systems to obtain more predictive and translational data. Conventional animal models often fail to fully replicate the molecular and cellular mechanisms involved in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Creative Biolabs addresses this challenge by offering human iPSC-based disease models that closely mimic patient-specific neurological pathology and cellular behavior. "Our integrated stem cell platform enables researchers to generate highly characterized neuronal cell types and disease-specific models with improved reproducibility and physiological relevance," said a senior scientist at Creative Biolabs. "We aim to support global neuroscience researchers in accelerating therapeutic discovery for Alzheimer's disease and other neurodegenerative disorders." iPSC Reprogramming Services Creative Biolabs provides comprehensive iPSC reprogramming services using multiple non-integrating technologies, including: Episomal vector-based reprogramming Sendai virus reprogramming mRNA-based reprogramming methods These approaches help maintain genomic stability while minimizing integration-associated risks, making the generated iPSC lines ideally suitable for downstream disease modeling, regenerative medicine research, and drug screening applications. The company supports reprogramming from a wide range of somatic cell sources and offers extensive pluripotency characterization and quality control analysis. Specialized Neuronal Differentiation Capabilities Creative Biolabs provides specialized neuronal differentiation services capable of generating high‑purity neural cell populations tailored to research needs. These include dopaminergic, GABAergic, and glutamatergic neurons, as well as motor and sensory neurons, astrocytes, and microglia. The resulting human iPSC‑derived neural cells are optimized for a wide range of applications, such as neurodegenerative disease modeling, high‑throughput drug screening, neurotoxicity assessment, biomarker discovery, and mechanistic studies. A key highlight of the expanded platform is the development of advanced Alzheimer's disease iPSC models . Using CRISPR/Cas9 genome editing, Creative Biolabs introduces clinically relevant mutations—such as those in APP, PSEN1, and PSEN2—to recapitulate hallmark AD pathologies. These engineered models enable in‑depth investigation of amyloid‑beta accumulation, tau hyperphosphorylation, synaptic dysfunction, and neuroinflammatory processes. The models are suitable for both basic neuroscience research and preclinical therapeutic evaluation, helping pharmaceutical and biotechnology companies improve target validation and candidate screening efficiency. Supporting Global Drug Discovery and Translational Medicine By integrating stem cell reprogramming, neuronal differentiation, and disease-specific engineering into a single workflow, Creative Biolabs simplifies complex neuroscience research processes and reduces technical barriers for research teams worldwide. Researchers interested in accelerating Alzheimer's disease and neurodegenerative disease drug discovery can explore Creative Biolabs' iPSC reprogramming services, neuronal differentiation platform, and customized disease models for translational neuroscience applications. To learn more or to request custom iPSC disease models, please visit https://www.creative-biolabs.com/stem-cell-therapy/ . About Creative Biolabs Creative Biolabs is a global biotechnology company providing advanced stem cell technologies, disease modeling services, and custom research solutions for regenerative medicine, neuroscience, and drug discovery.
- May 27, 2026Science
Creative Diagnostics Expands Preclinical CRO Services with Advanced MERS-CoV Animal Models to Accelerate Coronavirus Vaccine and Drug Development
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics has announced the expansion of its preclinical portfolio with the launch of its specialized MERS-CoV Animal Model services. Designed to meet the critical global demand for effective Middle East Respiratory Syndrome Coronavirus (MERS-CoV) research, these models bridge the gap between in vitro discovery and clinical evaluation, providing a robust platform for testing novel vaccine candidates and antiviral therapies. MERS-CoV is an emerging zoonotic virus that is considered to be one of the major public health threats. Since 2012, there have been consistent monthly cases of MERS-CoV causing severe respiratory illness, resulting in the death of approximately 35% of confirmed patients. It is believed that the virus is transmitted from camels in Middle Eastern countries through contact between humans and animals. The viral genome structure provides crucial insights into its pathogenicity and associated virulence factors. However, recent studies indicate that our understanding of the development of novel therapeutic strategies aimed at inducing antiviral immunity remains limited. The severity of MERS-CoV infection underscores the urgent need for effective therapeutic approaches. The ongoing threat to global public health posed by MERS-CoV, coupled with the need for novel therapeutic strategies, has driven the development of animal models that can reliably reproduce MERS-CoV-associated pathology in human infections. With extensive expertise and cutting-edge resources, Creative Diagnostics is committed to providing reliable animal models for MERS-CoV infection. This enables clients worldwide to gain a deeper understanding of the virus's complex mechanisms. Backed by a dedication to scientific excellence, these models show great promise in advancing research into the intricate pathogenesis of MERS-CoV, assessing potential therapeutic interventions and accelerating the development of effective strategies to combat this potent virus. Creative Diagnostics' MERS-CoV animal models primarily include the MERS-CoV Virus Tracheal Intubation Infection Rhesus Monkey Model, and the MERS-CoV Virus Intranasal Infection Mouse Model. By addressing key conditions such as mortality rates associated with severe respiratory disease, the absence of neurological complications at high viral loads and sustained high levels of viral replication in the lungs, Creative Diagnostics' animal models simulate human infection with MERS-CoV. They retain the innate expression of the MERS-CoV host receptor DPP4 and feature genetically modifiable host genes, making them suitable for vaccine and therapeutic response studies. Creative Diagnostics' animal models provide researchers with a controlled experimental platform on which to study viral behaviour, transmission, immune responses, and potential therapeutic approaches. Creative Diagnostics also offers a range of services to support MERS-CoV animal model research, including pathological analysis, immune response profiling, vaccine and antiviral compound efficacy testing, and data analysis and interpretation. Creative Diagnostics will be showcasing these preclinical services, alongside their comprehensive suite of viral and bacterial infection models, at the upcoming ASM Microbe 2026 conference in Washington, D.C., from June 4-7, at booth #1608. Attendees are invited to meet with their scientific team to discuss custom study designs and partnership opportunities. For more information about the MERS-CoV Animal Model services or to request a consultation, please visit https://antiviral.creative-diagnostics.com/mers-cov-animal-model.html . About Creative Diagnostics Headquartered in New York, Creative Diagnostics is a consulting and experimental service provider specializing in virology and microbiology. The company provides comprehensive solutions to conquer obstacles in virology and microbiology research, from high-security infrastructure provision, biosafety regulation elucidation, to expert viral system assistance.
- May 27, 2026Science
CD Bioparticles Launches Custom Development Services for Quantum Dot Lateral Flow Assays
With years of experience in the pharmaceutical and life science sectors, CD Bioparticles has announced the expansion of its specialized services for Quantum Dot Lateral Flow Assay (LFA) development. This suite of services can replace traditional gold nanoparticles with high-performance quantum dots, offering unprecedented sensitivity and quantitative precision for point-of-care testing (POCT). Point-of-care testing technology has exceptional capabilities for detecting biomarkers for a wide range of diseases thanks to its speed, ease of use, efficiency and cost-effectiveness. One such POCT strategy is the lateral flow immunoassay. It is a well-established testing platform and a powerful tool for rapid, low-cost detection as it requires no specialized equipment, and results can be observed directly with the naked eye. To improve the sensitivity and specificity of LFA and enable the quantitative analysis of test results, researchers have developed fluorescence immunochromatographic assays that use fluorescent reporter molecules. Compared to conventional methods, fluorescent immunoassays offer greater sensitivity as they produce higher-intensity bands on both the test and control lines. Quantum dots (QDs) are a highly promising class of fluorescent reporter molecule. These are minute semiconductor nanocrystals with diameters ranging from 2 to 10 nanometres. They possess unique electronic properties that lie between those of bulk semiconductors and discrete molecules, partly due to their high specific surface area. The most intuitive manifestation of this is the phenomenon of fluorescence, whereby the nanocrystals emit different colours depending on their size. CD Bioparticles offers custom services to assist researchers in developing quantum dot lateral flow assays. The company's services range from custom nanoparticle conjugates to fully optimizing lateral flow assays. Due to their high sensitivity, excellent photostability, ease of functionalization, multiplexing capabilities, and potential for quantitative analysis, quantum dot lateral flow assays are widely used in medical diagnostics, environmental monitoring, food safety testing, and biomarker detection. CD Bioparticles offers a comprehensive range of quantum dot lateral flow assay development services, including covalent conjugation of antibodies/proteins to quantum dots, conjugation of aptamers/oligonucleotides to quantum dots, optimization of antibody-based sandwich, direct and competitive lateral flow assays, optimization of aptamer/oligonucleotide-based lateral flow assays, quantitative detection and bulk production. CD Bioparticles' dedicated technical support team has extensive experience in providing comprehensive services covering sample preparation, selection of key materials, experimental protocol design, and validation of detection methods. The company possesses specialist expertise in optimizing running buffers, conjugation methods and nanoparticles. The company can assist clients in transferring and optimizing existing proof-of-concept detection methods into rapid flow cytometry-based protocols. The company also possesses large-scale production capabilities and can manufacture high-quality nanoparticles, such as gold colloids, upconversion nanoparticles and quantum dots, for use in rapid diagnostic testing. The company can supply uniform nanoparticles with varying sizes and surface properties for LFA development. For more information on the Quantum Dot Lateral Flow Assay development services or to inquire about a custom project, please visit https://www.cd-bioparticles.com/services/quantum-dot-lateral-flow-assay-development.html . About CD Bioparticles CD Bioparticles is a leading manufacturer and supplier of various nanoparticles, microparticles, and coatings for R&D as well as commercialization across different application areas, including in vitro diagnostics, biochemistry, cellular analysis, cell separation, and immunoassay. The company also offers various custom services, including chemical surface-functionalization, fluorescent modification, antibody immobilization, as well as nucleic acid and oligo conjugation to meet client specifications.
- May 25, 2026Science
Creative Biolabs Expands Precise Gene Editing and Donor Vector Services
Creative Biolabs, a global leader in biotechnology solutions, has announced the expansion of its advanced CRISPR-based gene editing and custom donor vector construction services. This initiative aims to support global researchers in overcoming efficiency bottlenecks in precise genomic modifications, ultimately accelerating preclinical gene therapy and therapeutics discovery. High-efficiency homology-directed repair (HDR) remains a critical factor for successful gene knock-in applications. Creative Biolabs addresses this challenge by optimizing donor vector design and construction strategy. By integrating cutting-edge technologies, the company delivers streamlined solutions that maximize targeting accuracy while reducing off-target risks. How Creative Biolabs Resolves Genomic Efficiency Bottlenecks Traditional gene editing workflows often suffer from low knock-in rates and time-consuming design phases. To streamline this process, the scientific team at Creative Biolabs has integrated sophisticated bioinformatics with next-generation delivery platforms, providing a highly reliable workflow: Custom Donor Vector Construction: Precision engineering of HDR donor templates (plasmid, rAAV, and ssDNA) and optimized delivery vehicles (including lentivirus for CRISPR machinery) tailored for optimal HDR efficiency. CRISPR-Cas9 System Optimization: Advanced guide RNA (gRNA) design and Cas9 protein selection to maximize cleavage specificity. Disease Modeling Applications : Reliable construction of stable cell lines and disease-specific models for oncology, neurology, and rare genetic disorders. Rigorous Quality Validation: Comprehensive validation protocols, including next-generation sequencing (NGS), to guarantee sequence integrity and pinpoint precision. "Our mission is to eliminate the design and manufacturing burdens that scientists face daily in genome engineering," stated a senior scientist at Creative Biolabs. "By delivering fully validated, high-purity donor vectors, we enable worldwide research laboratories to shift their focus away from routine molecular biology and entirely toward downstream functional validation and therapeutic target discovery." Driving Biotech Innovations from Concept to Model By providing scalable and highly customizable contract research options, Creative Biolabs helps biotechnology enterprises shorten their R&D timelines. This optimized approach ensures a seamless transition from initial computational design to validated cell or animal disease models, ensuring superior cost-effectiveness and reproducibility. Explore high-efficiency genome engineering solutions or request a custom project quote: https://www.creative-biolabs.com/gene-therapy/ . About Creative Biolabs Creative Biolabs is a premier biotechnology partner specializing in specialized contract research services. Grounded in advanced molecular biology platforms, the company offers end-to-end gene therapy solutions, including precise CRISPR/Cas9 genome editing, high-fidelity donor vector design, and comprehensive disease modeling support to advance global biomedical innovation.
- April 30, 2026Science
Bridging the Gap Between Ecological Restoration and Environmental Validation: CD BioSustainable Strengthens Integrated Environmental Solutions
CD BioSustainable recently announced the launch of an integrated environmental management solution, combining ecological restoration services with environmental degradation testing services . This measure aims to solve the current industry problem of a lack of verification based on real environmental conditions in the process of ecological restoration, and improve the scientificity and evaluability of environmental governance projects. In the context of the continuous deterioration of the environment, ecological restoration has become an important governance measure. However, there is a common problem in the industry that many projects focus on short-term indicator improvements, but lack a systematic assessment of whether pollutants have truly degraded and the long-term stability of the remediation effect. In addition, traditional tests are mostly based on ideal experimental conditions and are difficult to reflect the actual degradation behavior in complex environments. To address this problem, CD BioSustainable has integrated ecological restoration with environmental degradation testing capabilities, forming an integrated technical path covering restoration and verification. In terms of ecological restoration, the company, based on environmental biotechnology expertise, supports multi-scenario governance of soil, water bodies, and waste gases, not only focusing on pollutant removal but also emphasizing the restoration of ecosystem functions. At the verification level, CD BioSustainable offers environmental degradation testing capabilities, which are used to assess the degradation characteristics of substances in different environments. Among them, biodegradation testing under environmental conditions analyzes the degradation pathways and efficiency by simulating real environmental factors such as temperature, humidity, and microorganisms, thereby narrowing the gap between laboratory research and practical applications. By integrating the capabilities of remediation and testing, this system can conduct a comprehensive assessment of the degradation degree of pollutants, environmental adaptability, and potential ecological impacts, providing continuous data support for environmental governance projects. This integrated model helps to enhance the verifiability and traceability of project results. "As the requirements for environmental governance continue to rise, merely having the ability to restore is no longer sufficient to meet the actual needs," a representative from CD BioSustainable stated. "By integrating ecological restoration with environmental degradation testing, we aim to promote the development of more reliable and sustainable environmental biotechnology solutions." As the industry's focus on scientific assessment and sustainability continues to grow, the technological approaches for integrating restoration and verification capabilities are gradually becoming an important development direction in the field of environmental governance. About CD BioSustainable CD BioSustainable focuses on environmental governance and the application of biotechnology and is dedicated to providing systematic environmental biotechnology solutions. By integrating ecological restoration and environmental degradation testing capabilities, the company offers multi-scenario technical support to research institutions, enterprises, and related organizations, promoting ecological restoration and sustainable development practices.
- April 27, 2026Science
Global Concern Grows as Shark Populations Decline Across Key Ocean Ecosystems
Recent conservation discussions across the global marine science community are drawing renewed attention to the rapidly declining populations of sharks and the growing urgency of coordinated protection efforts. Marine biologists, environmental organisations, and ocean advocates warn that the continued loss of these apex predators could trigger far‑reaching consequences for ocean ecosystems. Sharks occupy a critical role in maintaining ecological balance in the world’s oceans. As top predators, they help regulate populations of fish and other marine species, preventing imbalances that can damage coral reefs, seagrass beds, and other essential habitats. Researchers emphasise that when shark populations decline significantly, entire marine food chains can shift in ways that threaten biodiversity. Over the past several decades, shark populations have dropped dramatically in many parts of the world due to overfishing, habitat disruption, and the continued demand for shark fins in luxury food markets. Conservation experts note that millions of sharks are still killed annually, with many species experiencing population declines of more than 70 to 90 percent in some regions. In response, conservation initiatives are expanding efforts to raise awareness and encourage public participation in shark protection campaigns. Environmental advocates say that while government regulation plays a major role in limiting destructive fishing practices, public awareness and support remain essential components of long‑term conservation success. Organisations involved in marine protection have increasingly turned to digital platforms to inform audiences about the importance of sharks and the broader health of ocean ecosystems. Educational campaigns are helping to correct common misconceptions about sharks while highlighting their ecological importance. Initiatives such as those highlighted through Ever Wonder Adventure’s shark conservation awareness efforts provide information about the challenges sharks face and the actions individuals can take to support ongoing protection programs. Ocean conservation advocates emphasise that protecting sharks ultimately helps protect the entire marine environment. Healthy shark populations help stabilise fish populations, which in turn support fisheries, coastal economies, and the long‑term sustainability of marine ecosystems. Support for conservation initiatives is also expanding through community engagement programs, partnerships with environmental groups, and public education campaigns. Some initiatives encourage individuals to explore conservation resources and contribute to awareness projects designed to strengthen global support for shark protection. Information about these initiatives can be found through educational pages dedicated to shark preservation, including the campaign featured at https://everwonderadventure.com/save-sharks . Advocates say that continued public engagement will play a crucial role in reversing the decline of shark populations. Conservation supporters who wish to participate in broader environmental efforts are increasingly exploring ways to assist organizations working to safeguard marine biodiversity. Additional information about participation and conservation support initiatives is available through https://everwonderadventure.com/support-us . Marine conservation researchers stress that meaningful progress requires collaboration between governments, scientists, environmental organisations, and everyday citizens. While the challenges facing ocean ecosystems remain significant, growing awareness and coordinated action provide renewed hope that shark populations can recover and that marine ecosystems can remain resilient for future generations.
- April 27, 2026Science
STEMart Launches Comprehensive Suite of Advanced Particle Analyzers to Accelerate Innovation in Materials Science and Biotechnology
STEMart, a US-based provider of comprehensive services for all phases of medical device development, is pleased to announce the expansion of its analytical instrumentation portfolio with the launch of its advanced Particle Analyzer series. This new collection of high-precision instruments is designed to meet the rigorous demands of researchers and manufacturers in characterizing particle size, distribution, and surface properties across a variety of scientific disciplines. Precise analytical measurements are required on a daily basis in academic research and scientific laboratories across various fields, such as pharmaceuticals and cosmetics. These measurements include pH, weight, conductivity, and elemental analysis. Such measurements rely on specific analytical equipment and instruments, which must be reliable, cost-effective, durable and flexible. Particle analyzers are devices used to measure the size and characteristics of particles in a sample. Particle analysis is employed to study the size, shape and distribution of particles within materials, thereby providing a deeper understanding of their physical properties and behavioural characteristics, which is of paramount importance across numerous industrial and research sectors. Particle size can influence the physical and chemical properties of particulate materials, and is an important indicator of quality and performance. It also determines a material's flowability and compaction properties. Particle size analysis is a key technique for determining particle size distribution. In the pharmaceutical industry, for example, the particle size of active ingredients affects characteristics such as content uniformity, dissolution and absorption rates. Particle size analysis plays a crucial role in many fields, including nanotechnology, proteins, polymers, cosmetics, fertilizers, soils, and abrasives. This technique can be used to calculate the average particle size and polydispersity index. Two methods are commonly used for particle size analysis: microscopy and dynamic light scattering. Microscopy has the advantage of providing morphological data on nanoparticles, as well as the size of individual particles. However, determining the size distribution of nanoparticles using this method is difficult. Dynamic light scattering, on the other hand, provides the average hydrodynamic size of nanoparticles and their size distribution within the corresponding nanofluid sample. STEMart's newly launched range of particle analyzers offers the necessary sensitivity and precision to meet customers' needs for accurate and reliable particle analysis, ensuring product quality, stability and compliance in highly sensitive environments. For example, the STEM-AIAE-0543-LGZ Particle Analyzer uses digital imaging technology to measure the size and shape of microscopic particles in fluid media. Image-based particle analysis enables the comprehensive characterization of subvisible particles, API aggregates, and impurities in biopharmaceuticals, as well as mammalian cells, microplankton, emulsions, and advanced materials. In addition, STEMart continues to offer a diverse range of instrumentation, including particle counters, particle metrology systems, and laser light scattering systems. This ensures that cutting-edge technology remains accessible to laboratories of all sizes and budget requirements. For more information about STEMart's Particle Analyzer offerings and other analytical instrumentation, please visit https://www.ste-mart.com/category-particle-analyzer-surface-analyzer-liquid-analyzers-80.htm . About STEMart STEMart is an industry-leading eCommerce platform incorporated with an extensive global footprint and a broad portfolio of more than 10,000 products. It aims to provide better lab materials, medical instruments and consumables, excellent technologies, and high-quality services to global customers in the fields of science, technology, and engineering, from the discovery stage upward to the manufacturing process. STEMart is dedicated to enhancing research and biotech production with simpler and safer protocols to access better health worldwide.
- April 27, 2026Science
Creative Diagnostics Launches Specialized Flow Cytometry Antibodies to Advance Non-Human Primate Research
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced the launch of its new Flow Cytometry Antibodies . This specialized collection is specifically engineered to address the critical need for highly specific, reliable reagents in non-human primate (NHP) biomedical research and preclinical drug development. Although non-human primates account for only a small proportion of the animals used in biomedical research, they remain important research models due to their high degree of similarity to humans in terms of genetic makeup, anatomy, physiology and behaviour. Key medical advances have been driven by research conducted using non-human primates, primarily monkeys, saving or improving the lives of millions of people. Prior to clinical trials, NHP models play a crucial role in evaluating therapeutic antibodies, biologics, and immunomodulatory drugs. Flow cytometry has become an essential analytical tool for studying immune responses in these models. Enabling high-dimensional analysis of immune cell populations and their activation states, it allows researchers to assess changes in immune cell subsets, functional markers, and cytokine expression in response to drug candidates, vaccines, or disease progression. However, researchers often face a significant challenge in the form of the limited availability of antibodies that are specifically validated to target monkey immune markers. This means that many laboratories are forced to rely on anti-human antibodies that exhibit cross-reactivity, which can lead to inconsistent results, weak signals or poor reproducibility. To address this issue, Creative Diagnostics has developed a portfolio of high-quality antibodies that target monkey immune cell surface markers specifically. These antibodies enable precise immune monitoring and support the reliable phenotyping of non-human primate immune systems and translational research. Creative Diagnostics' rabbit anti-monkey flow cytometry antibody panel has been developed to detect surface markers on monkey immune cells. Designed to support preclinical pharmacology studies, immune profiling and mechanistic research in non-human primate models, these antibodies help pharmaceutical and biotechnology companies to accelerate the development of innovative therapies. The panel enables precise characterization of immune cell subsets and signaling pathways involved in drug responses, disease progression, and immune regulation in NHP research. The broad coverage of markers allows researchers to construct multiparametric flow cytometry panels and facilitates in-depth immunophenotyping analyses in non-human primates. Furthermore, these antibodies have been optimized to exhibit high specificity for non-human primate antigens, enabling the accurate detection of primate immune markers with minimal background signal. All the antibodies in this panel are produced using recombinant antibody technology and demonstrate an excellent signal-to-noise ratio. These rabbit anti-monkey flow cytometry antibodies are ideal for various applications in NHP research, including preclinical drug development, immunophenotyping, mechanism of action studies and safety and immunotoxicity assessments. For more information about the Rabbit Anti-Monkey Flow Cytometry Antibody Panel or to view the full product catalog, please visit https://www.creative-diagnostics.com/flow-cytometry-antibodies-for-non-human-primate-research.htm . About Creative Diagnostics Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components, and critical assay reagents. In addition to providing contract R&D and biologic manufacturing services for diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market, the company aims to continue to act as a trusted source for all researchers’ assay development and manufacturing needs.
- April 24, 2026Science
Creative Biolabs Expands Research Platforms to Accelerate Immunotherapy Development
Creative Biolabs, a global leader in biotechnology services, today announced the expansion of its specialized research platforms designed to accelerate the discovery and development of innovative immunotherapies. By integrating expertise in mouse macrophages, complement C1 Inhibitor functional testing, and immortalized cell line modeling, the company is reinforcing its commitment to advancing immune‑based solutions for complex diseases. Empowering Immunology with Macrophages Macrophages play a central role in innate immunity, inflammation, and therapeutic response. Creative Biolabs provides comprehensive macrophage products from different species and sources, including polarized M1 and M2 phenotypes.. Customers who use the mouse macrophage bone marrow product speak very highly of it. One customer shared: "These cells saved us the trouble of isolating bone marrow ourselves. The QC report was detailed, and the lot‑to‑lot consistency was impressive. Highly recommended for labs with limited animal resources." Precision Testing with Complement C1 Inhibitor Assays The complement system is a critical regulator of immune balance, and dysfunction can lead to severe clinical conditions. Creative Biolabs' complement C1 inhibitor (C1-INH) functional assays deliver sensitive, reproducible results that help researchers evaluate complement activity in both health and disease. By enabling precise measurement of C1‑INH activity, the platform supports therapeutic development for hereditary angioedema (HAE), autoimmune disorders, and other complement‑related pathologies. "There is no need for any concern regarding the efficiency of project completion. The estimated cycle for completing the C1‑INH functional test typically ranges from 3 to 7 business days, except under special circumstances," said the chief scientist at this company. Breakthroughs in Immortalized Cell Line Modeling To bridge immunology and neuroscience, Creative Biolabs has expanded its suite of immortalized cell line models, including neurons, astrocytes, and microglia. These tools are essential for studying neuroinflammation and neurodegenerative diseases. With long‑term stability, genetic manipulability, and cost‑effectiveness, immortalized cell lines are indispensable for drug screening, gene function studies, and immunotherapy development. By integrating neuroimmune research into its portfolio, Creative Biolabs is helping scientists uncover how immune mechanisms influence brain health and disease progression. "Our expanded platforms demonstrate our unwavering commitment to advancing immunotherapy research," said a spokesperson for Creative Biolabs. "By combining expertise in people, technology, and platforms, we are equipping researchers with the tools they need to accelerate discovery." To learn how Creative Biolabs can elevate your work, please explore https://neuros.creative-biolabs.com/. About Creative Biolabs Creative Biolabs is a global leader in biotechnology services, specializing in custom solutions for immunology, neuroscience, and therapeutic development. With cutting‑edge platforms and expert teams, the company supports researchers worldwide in achieving scientific breakthroughs that pave the way for innovative therapies.
- April 23, 2026Science
Cattail Overgrowth as Aquatic Nuisance: Management Guide Released
AquaticWeed.org has released a cattail management guide designed to help lakefront landowners address overgrowth widely recognized as an aquatic nuisance affecting water bodies and recreational uses. The resource provides practical, science-backed strategies for restoring ecological balance while preserving the beneficial functions of native cattail populations. Expert-reviewed by Dr. Margaret Callahan, Ph.D. in Aquatic Ecology, and James Whitmore, M.S., Certified Lake Manager, the guide integrates university extension research, government guidance, and field studies into actionable protocols tailored to diverse property conditions. More information is available at https://aquaticweed.org/emergent-aquatic-weeds/cattails/ Dense cattail stands have expanded dramatically across the Great Lakes region and Prairie Pothole Midwest, driven by nutrient enrichment from agricultural runoff and atmospheric nitrogen deposition. According to research cited in the guide, cattail monocultures substantially reduce plant biodiversity compared to native mixed wetland communities, displacing diverse native species that support invertebrates, waterfowl, and nesting birds. These dense stands impair recreational activities such as fishing and boating while reducing open water and creating mosquito breeding habitat linked to disease vectors including West Nile Virus. The ecological and recreational consequences have prompted lakefront property owners to seek effective, sustainable solutions. Control methods vary based on property size, water body conditions, and management goals. The guide outlines three primary pathways: chemical treatment using systemic herbicides such as imazapyr or glyphosate, which received an "Excellent" rating in U.S. Army Corps of Engineers aquatic herbicide trials; water level manipulation through fall drawdown, which exposes rhizomes to freezing temperatures; and mechanical removal combined with replanting of native alternatives. Each method requires specific timing and site conditions to achieve long-term success, and the guide provides step-by-step protocols to help landowners select the most appropriate approach. A critical barrier for many lakefront landowners is navigating state permitting requirements, which vary significantly across jurisdictions. In states such as Minnesota and Wisconsin, permits are required for the destruction of emergent vegetation like cattails, for cutting or pulling submerged vegetation in areas larger than 2,500 square feet, and for applying herbicides or algaecides. The guide clarifies these regulatory requirements and helps property owners avoid costly mistakes by providing guidance on navigating regulatory requirements, including permits. Rather than eliminating cattails entirely, the guide emphasizes achieving a sustainable balance that preserves ecological benefits while restoring water access and biodiversity. Limiting cattail coverage to approximately 10 percent of the shoreline margin is often recommended for small ponds, according to some resources. This approach maintains cattail's role in wildlife habitat, nutrient filtration, and shoreline stabilization while preventing the formation of dense monocultures that degrade water quality and recreational value. The resource combines expert research with practical decision-making support, including case studies, identification tips, and management protocols designed for lakefront property owners. By integrating scientific evidence with actionable steps, the guide addresses the need for informed management plans that consider not only rooted plants but also animal communities, watershed inputs, and recreational needs. For access to the guide and additional resources, visit https://aquaticweed.org
- April 23, 2026Science
Creative Biolabs Advances Pre-targeted In Vivo Imaging with Bioorthogonal Click Chemistry and Site-specific Bioconjugation
Creative Biolabs expands its bioorthogonal click chemistry and site-specific bioconjugation services, delivering pre-targeted in vivo imaging solutions that accelerate precision biomedical research in oncology, immunology, neuroscience, and drug development. Addressing the Core Bottlenecks in In Vivo Imaging Achieving high-fidelity in vivo imaging remains a major challenge in biomedical research. Conventional PET/CT and fluorescence imaging approaches often suffer from: High background signal due to nonspecific accumulation (e.g., liver uptake) Limited target specificity Interference with native biological processes Poor performance in complex environments such as blood-brain barrier (BBB) systems Creative Biolabs addresses these limitations through bioorthogonal click chemistry-enabled pre-targeting strategies, enabling high-contrast imaging with minimal biological perturbation. Bioorthogonal Click Chemistry: Copper-free Precision in Living Systems Bioorthogonal chemistry has evolved beyond a conceptual framework into a toolkit of highly selective, copper-free reactions suitable for in vivo applications. Creative Biolabs supports multiple industry-standard bioorthogonal ligation platforms, including: SPAAC (Strain-Promoted Azide–Alkyne Cycloaddition) — copper-free, fast kinetics for i n vivo labeling IEDDA (Inverse Electron-Demand Diels–Alder) — ultrafast reaction rates ideal for pre-targeted imaging workflows Staudinger Ligation — biocompatible ligation with minimal off-target effects These copper-free click chemistry systems eliminate the cytotoxicity associated with Cu(I)-catalyzed reactions, making them particularly suitable for live-cell and preclinical in vivo studies. Pre-targeted Imaging: Solving Signal-to-Noise Challenges A major advancement enabled by bioorthogonal chemistry is pre-targeted imaging, which separates targeting and signal generation into two steps: Targeting moiety (e.g., antibody) accumulates at the disease site A small bioorthogonal probe reacts selectively in situ This approach: Reduces background signal from circulating probes Minimizes off-target accumulation (e.g., hepatic uptake) Enables imaging in challenging systems such as CNS and tumor microenvironments Compared to traditional direct-labeling strategies, bioorthogonal pre-targeting significantly improves signal-to-noise ratio and temporal resolution. In Vivo Imaging Solutions for Precision Biomedical Research Creative Biolabs integrates bioorthogonal chemistry with advanced bioconjugation platforms to deliver: High-resolution molecular imaging with minimal background interference Site-specific labeling for improved reproducibility Compatibility with PET, fluorescence, and multimodal imaging systems "Traditional imaging methods often struggle with specificity and background noise," said a senior scientist at Creative Biolabs. "By leveraging copper-free bioorthogonal click chemistry, we enable highly selective reactions in vivo , supporting precise visualization in complex biological systems." Customized Bioconjugation Services: From Concept to Application Creative Biolabs offers fully customized, site-specific bioconjugation solutions, including: Antibody-drug conjugates (ADCs) Fluorescent and radiolabeled probes Metabolic glycan labeling strategies Protein and peptide modification platforms Each project is optimized for: Reaction efficiency and stability Batch-to-batch reproducibility Compatibility with preclinical imaging workflows Compliance Statement All products and services provided by Creative Biolabs are intended for Research Use Only (RUO) and are designed exclusively for preclinical research applications. They are not intended for diagnostic or therapeutic use in humans. Download the latest technical guide on bioorthogonal pre-targeted imaging strategies and site-specific bioconjugation approaches: https://www.creative-biolabs.com/bioconjugation/. About Creative Biolabs Creative Biolabs is a leading biotechnology company specializing in bioorthogonal click chemistry, site-specific bioconjugation, and in vivo imaging solutions. With extensive expertise in pre-targeted imaging and precision labeling technologies, the company provides customized strategies to support cutting-edge biomedical research worldwide.
ALL NEWS
- 2026 Marketing Stack for Small Businesses: Tools & Channels Guide Released
- Blu Ocean Innovations Launches Blu Tsunami, an AI-Powered Local Marketing System
- Tree Frogs Showrooms: New Showrooms Now Open in Austin and San Antonio
- Love Tales Reveals Personalized Love Books As The New Go-To Gifts For Couples
- Voghion Adapts Its Platform To Cater To Gen Z Discovery Shopping Habits
- IVY Club by Zysphere Says Authenticity Is Becoming the Defining Edge in AI-Era Admissions
- French Optical Fashion, Inc. announces one-stop optometrist service in Manhattan
- Illinois Dump Trailer Prices & Specs: Buyer's Report For Contractors Released
- South Calgary Neurodivergent Child Health: Naturopathic Support Services Expand
- French Optical Fashion, Inc. expands Lindberg frames gallery in Manhattan
- Dear Klairs Expands Its US Presence Through OLIVE YOUNG Store Entry Promotion
- Men's Initiation Vision Fast: 2026 Wilderness Quest Program Dates Announced
- Absolute Water Compliance Provides New Legionella Risk Assessment Services In Yorkshire
- Coastal Marine Group introduces local dock builder solutions for complex shorelines
- Dual Restoration highlights Brooklyn training milestone in water damage and restoration
- The Boxery announces expanded paper rolls options for ecommerce shippers
- Prime Window Cleaning combines service estimates for clearer window cleaning pricing
- China and Malaysia jointly deepen vocational education and work together to jointly build a base
COMMUNICATE. COMMAND. COMMERCE.
Lead the conversation of your brand & win more customers with MarketersMEDIA Solutions.
Explore Now
Google
RSS